Nektar Therapeutics
Income Statement
| Line Item | Jul 2025 | Jun 2025 | May 2025 | Mar 2025 | Feb 2025 | Dec 2024 | Nov 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $11.2M | — | $10.5M | — | — | — | $24.1M |
| Cost of Revenue | — | $0 | — | $0 | — | — | — | $4.4M |
| Gross Profit | — | $11.2M | — | $10.5M | — | — | — | $19.7M |
| Gross Margin | — | 100.0% | — | 100.0% | — | — | — | 81.6% |
| Operating Expenses | ||||||||
| Research & Development | — | $29.9M | — | $30.5M | — | — | — | $35.0M |
| SG&A Expense | — | $17.1M | — | $24.3M | — | — | — | $19.0M |
| Operating Income | — | $-36.2M | — | $-44.5M | — | — | — | $-34.3M |
| Operating Margin | — | -324.2% | — | -425.8% | — | — | — | -142.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-39.4M | — | $-46.4M | — | — | — | $-37.0M |
| Income Tax Expense | — | $-188.0K | — | $52.0K | — | — | — | $9.0K |
| Net Income | — | $-41.6M | — | $-50.9M | — | — | — | $-37.1M |
| Net Margin | — | -372.2% | — | -486.4% | — | — | — | -153.6% |
| EPS (Basic) | — | $-2.95 | — | $-3.62 | — | — | — | $-2.66 |
| EPS (Diluted) | — | $-2.95 | — | $-3.62 | — | — | — | $-2.66 |
| Shares Outstanding (Basic) | 19.0M | 14.1M | 186.1M | 14.1M | 186.1M | 12.4M | 184.5M | 13.9M |
| Shares Outstanding (Diluted) | 19.0M | 14.1M | 186.1M | 14.1M | 186.1M | 12.4M | 184.5M | 13.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |